Viking Therapeutics (VKTX) Projected to Post Quarterly Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) is projected to release its Q4 2024 earnings data after the market closes on Wednesday, February 5th. Analysts expect Viking Therapeutics to post earnings of ($0.27) per share for the quarter. Investors that wish to register for the company's conference call can do so using this link.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same quarter in the prior year, the company earned ($0.25) EPS. On average, analysts expect Viking Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Viking Therapeutics Trading Down 6.1 %

VKTX stock traded down $2.04 during midday trading on Thursday, hitting $31.46. The company's stock had a trading volume of 9,332,501 shares, compared to its average volume of 3,986,872. The firm's 50-day moving average is $40.46 and its 200-day moving average is $54.01. Viking Therapeutics has a 12 month low of $23.81 and a 12 month high of $99.41. The company has a market cap of $3.51 billion, a PE ratio of -33.83 and a beta of 0.90.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $102.00 price target on shares of Viking Therapeutics in a report on Thursday. B. Riley started coverage on shares of Viking Therapeutics in a research note on Friday, November 22nd. They set a "buy" rating and a $109.00 target price on the stock. StockNews.com upgraded shares of Viking Therapeutics to a "sell" rating in a research note on Tuesday, October 15th. Piper Sandler lowered their price objective on shares of Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating on the stock in a research report on Thursday. Finally, William Blair restated an "outperform" rating on shares of Viking Therapeutics in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Viking Therapeutics has an average rating of "Buy" and a consensus target price of $107.08.

Insider Activity

In other Viking Therapeutics news, COO Marianna Mancini sold 54,215 shares of Viking Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $42.75, for a total transaction of $2,317,691.25. Following the transaction, the chief operating officer now owns 374,134 shares of the company's stock, valued at $15,994,228.50. The trade was a 12.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lawson Macartney sold 2,000 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $68.67, for a total transaction of $137,340.00. Following the completion of the sale, the director now directly owns 47,965 shares of the company's stock, valued at approximately $3,293,756.55. This trade represents a 4.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 301,014 shares of company stock valued at $12,920,189 in the last 90 days. Company insiders own 4.70% of the company's stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.